Novartis' heart failure drug Entresto has been on the ascent after a slower-than-expected debut on the market, and now the drug has an expanded FDA label that could widen its reach to millions of new ...
ENTRESTO The FDA has approved Entresto for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged 1 year and older. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results